Eli Lilly and Company
Patents, Design & Utilities
Last updated:
List of all Eli Lilly and Company patents 385 in total
| Status | Patent |
|---|---|
Application | Utility: IMIDAZOLIDINE COMPOUNDS Filling date: 18 Sep 2025 Issue date: 4 Mar 2021 |
Grant | Utility: Condensed thiophene derivatives useful as NaPi-IIb inhibitors Filling date: 18 Sep 2025 Issue date: 2 Mar 2021 |
Application | Utility: IgG Bispecific Antibodies and Processes for Preparation Filling date: 18 Sep 2025 Issue date: 25 Feb 2021 |
Application | Utility: ANTI-CD137 ANTIBODIES FOR COMBINATION WITH ANTI-PD-1 ANTIBODIES Filling date: 18 Sep 2025 Issue date: 25 Feb 2021 |
Application | Utility: ANTI-CD137 ANTIBODIES FOR COMBINATION WITH ANTI-PD-L1 ANTIBODIES Filling date: 18 Sep 2025 Issue date: 25 Feb 2021 |
Grant | Utility: Rapid-acting insulin compositions Filling date: 18 Sep 2025 Issue date: 23 Feb 2021 |
Application | Utility: Gripping Attachment for a Bottle Filling date: 18 Sep 2025 Issue date: 18 Feb 2021 |
Grant | Utility: ANGPTL3/8 complexes and methods of using the same Filling date: 18 Sep 2025 Issue date: 16 Feb 2021 |
Application | Utility: SYSTEM FOR CONTROLLING GAS GENERATION WITHIN A DRUG DELIVERY DEVICE Filling date: 18 Sep 2025 Issue date: 11 Feb 2021 |
Grant | Utility: DNA molecules encoding anti-IL-33 antibodies Filling date: 18 Sep 2025 Issue date: 9 Feb 2021 |
Grant | Utility: Anti-RANKL antibodies and uses thereof Filling date: 18 Sep 2025 Issue date: 9 Feb 2021 |
Application | Utility: (E)-1-(4-(DIMETHYLAMINO)BUT-2-ENOYL)PYRROLIDIN-3-YL 4-((3-ISOPROPYL-5-METHYLPYRAZOLO[1,5-A]PYRIMIDIN-7-YL)AMINO)PIPERIDINE-1-- CARBOXYLATE FOR INHIBITING CDK7 Filling date: 18 Sep 2025 Issue date: 4 Feb 2021 |
Application | Utility: GIPR-AGONIST COMPOUNDS Filling date: 18 Sep 2025 Issue date: 4 Feb 2021 |
Application | Utility: METHODS OF TREATING ULCERATIVE COLITIS Filling date: 18 Sep 2025 Issue date: 4 Feb 2021 |
Grant | Utility: Anti-CD137 antibodies Filling date: 18 Sep 2025 Issue date: 2 Feb 2021 |
Grant | Utility: Medical delivery device with axially expandable drive member Filling date: 18 Sep 2025 Issue date: 26 Jan 2021 |
Grant | Utility: Fatty acid modified urocortin-2 analogs for the treatment of diabetes and chronic kidney disease Filling date: 18 Sep 2025 Issue date: 19 Jan 2021 |
Application | Utility: CD73 INHIBITORS Filling date: 18 Sep 2025 Issue date: 7 Jan 2021 |
Grant | Design: Secured medication transfer set Filling date: 18 Sep 2025 Issue date: 5 Jan 2021 |
Application | Utility: GLUCAGON-LIKE PEPTIDE1 RECEPTOR AGONISTS Filling date: 18 Sep 2025 Issue date: 31 Dec 2020 |
Application | Utility: NASAL DRUG DELIVERY DEVICES Filling date: 18 Sep 2025 Issue date: 24 Dec 2020 |
Application | Utility: MEDICATION DELIVERY DEVICE WITH A SENSED ELEMENT Filling date: 18 Sep 2025 Issue date: 24 Dec 2020 |
Application | Utility: [1,2,4]TRIAZOLO[4,3-A]PYRAZIN-8-ONE DERIVATIVES Filling date: 18 Sep 2025 Issue date: 24 Dec 2020 |
Application | Utility: TREATMENT OF ANDROGEN DEPRIVATION THERAPY ASSOCIATED SYMPTOMS Filling date: 18 Sep 2025 Issue date: 17 Dec 2020 |
Application | Utility: DISUBSTITUTED PYRAZOLE COMPOUNDS Filling date: 18 Sep 2025 Issue date: 17 Dec 2020 |
Application | Utility: FUSION PROTEINS Filling date: 18 Sep 2025 Issue date: 17 Dec 2020 |
Application | Utility: INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL Filling date: 18 Sep 2025 Issue date: 17 Dec 2020 |
Grant | Utility: Medication injection device with automatic needle retraction following injection Filling date: 18 Sep 2025 Issue date: 15 Dec 2020 |
Grant | Utility: Pan-ELR+ CXC chemokine antibodies Filling date: 18 Sep 2025 Issue date: 8 Dec 2020 |
Grant | Utility: Determination of a dose set and delivered in a medication delivery device Filling date: 18 Sep 2025 Issue date: 8 Dec 2020 |
Application | Utility: MEDICATION DELIVERY SYSTEMS AND METHODS Filling date: 18 Sep 2025 Issue date: 3 Dec 2020 |
Application | Utility: ANTI-CD137 ANTIBODIES Filling date: 18 Sep 2025 Issue date: 3 Dec 2020 |
Grant | Design: Drug delivery device Filling date: 18 Sep 2025 Issue date: 1 Dec 2020 |
Grant | Design: Component for a drug delivery device Filling date: 18 Sep 2025 Issue date: 1 Dec 2020 |
Application | Utility: MEDICATION DELIVERY DEVICE WITH SYRINGE SENSING SYSTEM Filling date: 18 Sep 2025 Issue date: 26 Nov 2020 |
Grant | Design: Component for a drug delivery device Filling date: 18 Sep 2025 Issue date: 24 Nov 2020 |
Grant | Utility: 6-fluoro-2-methylbenzo[d]thiazol-5-yl compounds Filling date: 18 Sep 2025 Issue date: 17 Nov 2020 |
Application | Utility: 6-Fluoro-2-Methylbenzo[d]thiazol-5-yl Compounds Filling date: 18 Sep 2025 Issue date: 12 Nov 2020 |
Application | Utility: COMPOUNDS AND METHODS TARGETING INTERLEUKIN-19 Filling date: 18 Sep 2025 Issue date: 12 Nov 2020 |
Application | Utility: NEUREGULIN-4 COMPOUNDS AND METHODS OF USE Filling date: 18 Sep 2025 Issue date: 12 Nov 2020 |
Application | Utility: PARATHYROID HORMONE-ANTI-RANKL ANTIBODY FUSION COMPOUNDS Filling date: 18 Sep 2025 Issue date: 12 Nov 2020 |
Grant | Utility: Dispensing device with drive mechanism having converging ramps Filling date: 18 Sep 2025 Issue date: 10 Nov 2020 |
Application | Utility: SELECTIVE ESTROGEN RECEPTOR DEGRADERS Filling date: 18 Sep 2025 Issue date: 5 Nov 2020 |
Application | Utility: CLOSED LOOP CONTROL OF PHYSIOLOGICAL GLUCOSE Filling date: 18 Sep 2025 Issue date: 29 Oct 2020 |
Application | Utility: Incretin Analogs and Uses Thereof Filling date: 18 Sep 2025 Issue date: 22 Oct 2020 |
Application | Utility: METHODS OF USING AND COMPOSITIONS CONTAINING DULAGLUTIDE Filling date: 18 Sep 2025 Issue date: 22 Oct 2020 |
Grant | Utility: Pyrrolidinone compounds Filling date: 18 Sep 2025 Issue date: 20 Oct 2020 |
Application | Utility: ERGONOMIC CONNECTOR HUB FOR AN INFUSION SET Filling date: 18 Sep 2025 Issue date: 15 Oct 2020 |
Grant | Utility: Treatment of androgen deprivation therapy associated symptoms Filling date: 18 Sep 2025 Issue date: 13 Oct 2020 |
Grant | Design: Drug delivery device Filling date: 18 Sep 2025 Issue date: 13 Oct 2020 |
Showing 200 to 250 of 385 patents.